Akari Therapeutics plc ADS (AKTX) Live Share Price, Invest From India

Akari Therapeutics plc ADS Stock Performance

as on July 2, 2026 at 6:59 am IST

Day's Low
Day's High
$10.20
Day's Price Range
$11.86
$10.36
1.54%
Downside
14.48%
Upside
52 Week's Low
52 Week's High
$3.02
52-Week Price Range
$49.60
$10.36
70.90%
Downside
378.76%
Upside

Akari Therapeutics plc ADS share price movements today

Previous Close: $10.24
Open: $10.20
Volume: 296.2K
Day's Low - High: $10.20 - $11.86
52 Week Low - High: $3.02 - $49.60

Akari Therapeutics plc ADS Historical Returns

1 Month Return: -23.72 %
3 Month Return: + 120.32 %
1 Year Return: -78.02 %
3 Year Return: -92.47 %
5 Year Return: -99.26 %

Akari Therapeutics plc ADS Stock Fundamentals & Key Indicators

Check Akari Therapeutics plc ADS market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$15.8M

EPS (TTM)

-2.885

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-12.1M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-155.28%

Akari Therapeutics plc ADS vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Akari Therapeutics plc ADS with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Akari Therapeutics plc ADS	BUY	$15.8M	-99.26%	NA	0.00%	NA
Revolution Medicines Inc.	BUY	$41.0B	460.55%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$40.2B	77.34%	75.45	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$126.8B	145.65%	29.66	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$66.4B	8.51%	15.46	29.65%	0.58%

Stock Returns calculator for Akari Therapeutics plc ADS Stock including INR - Dollar returns

The Akari Therapeutics plc ADS stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Akari Therapeutics plc ADS investment value today

Current value as on today

₹24,729

Returns

-₹75,271

(-75.27%)

Returns from Akari Therapeutics plc ADS Stock

-₹77,768 (-77.77%)

Dollar Impact

₹2,497 (+2.5%)

Analyst Recommendation on Akari Therapeutics plc ADS Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Akari Therapeutics plc ADS. Average target price of $26.78

Akari Therapeutics plc ADS Share Price Target

Get share price movements and forecasts by analysts on Akari Therapeutics plc ADS.

What analysts predicted

61.31%UPSIDE

Target Price

$26.78

Current Price

$10.36

Analyzed by

7 Analysts

Target

$26.78

Akari Therapeutics plc ADS target price $26.78, a slight upside of 61.31% compared to current price of $10.36. According to 7 analysts rating.

Indian Investors' Interest in Akari Therapeutics plc ADS Stock

Search interest for Akari Therapeutics plc ADS Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: June 2, 2026 to July 2, 2026

Change:-50% versus previous 30 day period

Akari Therapeutics plc ADS Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	-	0	-	-	-	-
Gross Profit	-	0	-	-	-	0	-	-	-	-
Operating Income	-5	-5	-7	-2	-4	-3	-3	-7	-3	-15
EBITDA	-4	-5	-7	-2	-	-3	-1	-7	-4	-15
Interest Expense	-	-	0	0	0	0	0	0	0	0
Depreciation	0	0	-	-	0	-	-	-	-	-
Income Before Tax	-4	-5	-7	-2	-3	-3	-1	-7	-5	-15
Income Tax Expense	-	0	-	-	-	-	-	-1	0	0
Net Income	-4	-5	-7	-2	-3	-3	-1	-6	-5	-14
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-14251.10%	0.00%	0.00%	0.00%	0.00%

Akari Therapeutics plc ADS Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	0	0	0	0	0	0	0	-
Operating Income	-27	-34	-19	-24	-17	-17	-23	-16	-21	-17
EBITDA	-27	-37	-16	-24	-17	-17	-17	-10	-19	-17
Interest Expense	9	2	0	0	0	0	5	-	0	0
Depreciation	-	0	0	0	0	0	0	0	0	-
Income Before Tax	-18	-32	-23	-24	-17	-17	-17	-10	-19	-18
Income Tax Expense	0	-4	-3	-7	-2	0	-10	-	-	-1
Net Income	-18	-27	-19	-16	-17	-17	-17	-10	-19	-17
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Akari Therapeutics plc ADS Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-5	-7	-2	-3	-3	-1	-6	-7	-14
Operating Cash Flow	-4	-4	-1	-2	-2	-3	-2	-3	-2
Investing Cash Flow	-	-	-	-	0	-	-	-	-
Financing Cash Flow	1	7	0	2	2	3	1	5	0
Change in Cash	-2	2	-1	0	0	0	0	2	-2

Akari Therapeutics plc ADS Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-35	-23	-16	-17	-17	-17	-10	-19	-17
Operating Cash Flow	-31	-22	-12	-16	-18	-21	-16	-12	-10
Investing Cash Flow	9	9	-	-	-	-	-	0	-
Financing Cash Flow	15	0	12	25	14	25	7	10	13
Change in Cash	-5	-22	0	8	-4	3	-9	-1	2

Global Institutional Holdings in Akari Therapeutics plc ADS

Funds	Holdings
SBI Securities Co Ltd	0%
Advisor Group Holdings, Inc.	0%
EverSource Wealth Advisors, LLC	0%
Omnia Family Wealth, LLC	0%
CWA Asset Management Group, LLC	0%

See all

Insights on Akari Therapeutics plc ADS

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, AKTX stock has moved up by 120.3%
NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 600.1% return, outperforming this stock by 692.6%
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 407.7% return, outperforming this stock by 485.7%

About Akari Therapeutics plc ADS

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Organisation	Akari Therapeutics plc ADS
Headquarters	401 East Jackson Street, Tampa, FL, United States, 33602
Industry	Biotechnology
CEO	Mr. Abizer Gaslightwala
E-voting on shares	Click here to vote

Key Management of Akari Therapeutics plc ADS

Name	Title
Mr. Abizer Gaslightwala	CEO, President & Director
Mr. Kameel D. Farag	Interim Chief Financial Officer
Dr. Satyajit Mitra Ph.D.	Executive Director & Head of Oncology

FAQs

What is Akari Therapeutics plc ADS share price today?

Akari Therapeutics plc ADS share price today is $10.36 as on July 2, 2026 at 1:29 am IST at the close of the market. Akari Therapeutics plc ADS share today touched a day high of $11.86 and a low of $10.2.

What is the 52 week high and 52 week low for Akari Therapeutics plc ADS share?

Akari Therapeutics plc ADS share touched a 52 week high of $49.6 on September 25, 2025 and a 52 week low of $3.02 on May 12, 2026. Akari Therapeutics plc ADS stock price today i.e. July 2, 2026 at 1:29 am IST is closed at $10.36,which is 79.11% down from its 52 week high and 243.62% up from its 52 week low.

What is Akari Therapeutics plc ADS's market capitalisation today?

Akari Therapeutics plc ADS market capitalisation is $0.00T as on July 2, 2026 at 1:29 am IST.

How to invest in Akari Therapeutics plc ADS Stock (AKTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Akari Therapeutics plc ADS on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Akari Therapeutics plc ADS Shares that will get you 0.1448 shares as per Akari Therapeutics plc ADS share price of $10.36 per share as on July 2, 2026 at 1:29 am IST.

What is the minimum amount required to buy Akari Therapeutics plc ADS Stock (AKTX) from India?

Indian investors can start investing in Akari Therapeutics plc ADS (AKTX) shares with as little as ₹95.2475 or $1 (as of July 2, 2026 at 4:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹952.48 in Akari Therapeutics plc ADS stock (as per the Rupee-Dollar exchange rate as on July 2, 2026 at 4:38 am IST). Based on Akari Therapeutics plc ADS share’s latest price of $10.36 as on July 2, 2026 at 1:29 am IST, you will get 0.9653 shares of Akari Therapeutics plc ADS. Learn more about fractional shares .

What are the returns that Akari Therapeutics plc ADS has given to Indian investors in the last 5 years?

Akari Therapeutics plc ADS stock has given -99.26% share price returns and 26.8% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?